OPTIMIZE-1 Primary Analysis: Safety, Efficacy and Biomarker Results of a Phase 1b/2 Study Combining CD40 Agonist Mitazalimab with Mfolfirinox in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac).
Journal of Clinical Oncology(2024)
关键词
Metastatic Pancreatic Cancer
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要